Cancer screening implementation in Eastern Europeprimary
2 projects
Both CBIG-SCREEN and EU-TOPIA-EAST focus on improving organized screening programs for breast, cervical, and colorectal cancer in Eastern European settings.
Organization
INSTITUTUL ONCOLOGIC PROF DR ION CHIRICUTA CLUJ-NAPOCA
Romanian oncology institute specializing in cancer screening equity, HPV prevention, and NGS-based personalized therapy in Eastern European contexts.
Research institutehealthROThin data (2/5)
H2020 projects
3
As coordinator
0
Total EC funding
€547K
Unique partners
45
What they do
Their core work
The Ion Chiricuța Oncological Institute in Cluj-Napoca is Romania's leading specialized cancer treatment and research hospital. In the H2020 context, they contribute clinical expertise in cancer screening programs, particularly for cervical and colorectal cancers, and participate in standardizing next-generation sequencing (NGS) workflows for personalized cancer therapy. Their work focuses on improving cancer screening uptake among vulnerable and underserved populations in Eastern Europe, combining oncology clinical practice with health equity research.
Core expertise
What they specialise in
Health equity and access for vulnerable populationsprimary
2 projects
CBIG-SCREEN targets vulnerable women and EU-TOPIA-EAST emphasizes equitable screening, both addressing socioeconomic inequalities and migration-related barriers.
NGS-based personalized oncologysecondary
1 project
Instand-NGS4P involves integrated NGS workflows for personalized therapy across common and rare cancers, including pharmacogenetics and bioinformatics.
HPV and cervical cancer preventionsecondary
1 project
CBIG-SCREEN specifically addresses HPV screening, incentives for participation, and cervical cancer prevention among hard-to-reach populations.
Health economics and behavioral research in oncologyemerging
2 projects
Recent projects use discrete choice experiments and cost-effectiveness analysis to understand screening behaviors and design better incentive structures.
Evolution & trajectory
How they've shifted over time
Early focus
NGS standardization for personalized therapy
Recent focus
Equitable cancer screening implementation
Their earliest H2020 involvement (2020) was technical and laboratory-focused — standardizing NGS sequencing workflows, gene panels, and bioinformatics pipelines for personalized cancer treatment. By 2021, the focus shifted decisively toward public health and health equity: cancer screening programs, behavioral incentives, and addressing socioeconomic barriers to healthcare access. This evolution reflects a move from bench-side molecular diagnostics toward population-level cancer prevention and implementation science.
Moving toward implementation science and health equity research, making them a strong partner for projects addressing cancer prevention disparities in Central and Eastern Europe.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European18 countries collaborated
IOCN operates exclusively as a consortium participant or third party — they have never coordinated an H2020 project. With 45 unique partners across 18 countries, they join large, multi-national consortia where they contribute clinical data, patient cohorts, and regional expertise from a Romanian oncology context. Their role is that of a domain expert embedded in broader European networks rather than a project driver.
Despite only 3 projects, IOCN has built a wide network of 45 partners across 18 countries, reflecting the large consortium sizes typical of EU health research. Their geographic connections span broadly across Europe, with particular relevance to Eastern European health systems.
Why partner with them
What sets them apart
As Romania's premier oncological institute, IOCN offers something few Western European partners can: direct access to patient populations and healthcare systems in a country where cancer screening uptake remains low and health inequalities are pronounced. This makes them an essential partner for any project that needs to demonstrate impact in Eastern European healthcare contexts. Their combination of clinical oncology infrastructure with health equity research is uncommon for a hospital-based research center.
Notable projects
Highlights from their portfolio
- EU-TOPIA-EASTLargest funding (EUR 400,475) and addresses the critical gap in organized cancer screening across Eastern Europe — a politically and scientifically high-priority topic.
- Instand-NGS4PPre-commercial procurement (PCP) project standardizing NGS workflows for personalized cancer therapy — a different, more technical direction compared to their screening work.
Cross-sector capabilities
Public health policy and implementation scienceHealth economics and cost-effectiveness analysisGenomics and molecular diagnosticsMigration and social inclusion research
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →